China is a major global producer of raw pharmaceutical materials and an even larger consumer of medicines. However, the chemical drugs produced domestically currently lack independent intellectual property rights, with 97% being generic drugs, placing China at a disadvantage in international competition. In response, relevant experts have proposed suggestions for the future R&D direction and product structure adjustment of Chinese pharmaceutical companies. Adjusting the product structure to implement more "three-dimensional cross" approaches. Nowadays, people increasingly value health and improving quality of life. Coupled with the accelerated construction of the public health system, the improvement of disease prevention and control systems, the strengthening of rural medical and health infrastructure, and the establishment of new cooperative medical systems, this has created favorable conditions for the pharmaceutical economy.

In the near future, some hypertension patients may be able to effectively control their blood pressure simply by receiving a vaccine injection. This therapeutic vaccine is the result of years of research by a Swiss pharmaceutical company. Currently, the vaccine is still in small-scale clinical trials, with 48 hypertension patients having completed one injection course. The expected blood pressure-lowering effect can last for about 4 months. It is reported that the vaccine will be marketed within five years, and the related research results have been published in the renowned British medical journal The Lancet. The hypertension vaccine mainly targets the renin-angiotensin system; once injected into the body, the vaccine "infects" the patient and stimulates the immune system

On August 18, more than 50 pharmacy owners from 11 cities in Zhejiang Province gathered in Hangzhou to officially establish the "Zhejiang Province Pharmaceutical Retail (Chain) Enterprise Joint Procurement Center." They decided to collectively conduct drug bidding with pharmaceutical manufacturers to reduce costs and seek new development opportunities. This is the first non-profit joint drug procurement center in Zhejiang Province and even nationwide. Industry insiders say this marks a shift in the pharmacy industry from passive price reductions to "active initiatives." The development of pharmacies has reached a freezing point. One of the initiators of this joint procurement center, Lin Zhenhua, General Manager of Hangzhou Buyi Pharmacy, told reporters that since 2002